With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting
Eka Care will provide a six-month complimentary trial period to all members who register before December 31, 2021
The investment will be used to develop affordable Point of Care labs with 70+ tests. Mylab will start deploying systems with its lab partners from Nov 2021
The investment will be used to develop affordable Point of Care labs with 70+ tests. Mylab will start deploying systems with its lab partners from Nov 2021
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
This award is open to all currently operational laboratories pertaining to testing, calibration & medical including their proficiency testing providers & reference material producers located in India
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Barbara Engelhardt moves her computational and statistics lab to Gladstone
Study to explore heterologous regimen of COVID-19 vaccines from different manufacturers in adolescents 12-16 years of age
Godrej and Boyce and Isgec Engineering have confirmed receiving the orders
Subscribe To Our Newsletter & Stay Updated
